|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0030705,
umls-concept:C0031327,
umls-concept:C0036341,
umls-concept:C0058698,
umls-concept:C0073393,
umls-concept:C0086466,
umls-concept:C1272883,
umls-concept:C1272936,
umls-concept:C1320098,
umls-concept:C1533685,
umls-concept:C2827063
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2005-2-15
|
|
pubmed:abstractText |
Thirteen patients with schizophrenia received injections of 25, 50, or 75 mg of long-acting risperidone every 2 wk. Brain D2 receptor occupancy was assessed with [11C]raclopride 2 wk after the last (fifth) injection (day 71) in seven subjects and 2 wk after the third injection (day 44) in one subject. Stable plasma concentrations were reached after the third injection and steady-state concentrations of the active moiety (risperidone + 9-hydroxyrisperidone) after the fourth injection. Steady-state plasma concentrations were maintained for 4-5 wk after the last injection and then declined rapidly. After injections of 25, 50 and 75 mg on day 44 or day 71, D2 receptor occupancy ranged from 25-48%, 59-83% and 62-72% respectively, while plasma active-moiety levels ranged from 4.4-8.8, 15.0-31.1 and 22.5-26.3 ng/ml respectively. The results indicate that brain D2 receptor occupancy at steady state after injections of long-acting risperidone was in the range found in patients effectively treated with 2-6 mg of oral risperidone.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1461-1457
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
8
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
27-36
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15710053-Administration, Oral,
pubmed-meshheading:15710053-Adult,
pubmed-meshheading:15710053-Antipsychotic Agents,
pubmed-meshheading:15710053-Binding, Competitive,
pubmed-meshheading:15710053-Brain,
pubmed-meshheading:15710053-Delayed-Action Preparations,
pubmed-meshheading:15710053-Dopamine Antagonists,
pubmed-meshheading:15710053-Dose-Response Relationship, Drug,
pubmed-meshheading:15710053-Drug Administration Schedule,
pubmed-meshheading:15710053-Female,
pubmed-meshheading:15710053-Humans,
pubmed-meshheading:15710053-Image Processing, Computer-Assisted,
pubmed-meshheading:15710053-Injections, Intramuscular,
pubmed-meshheading:15710053-Isoxazoles,
pubmed-meshheading:15710053-Male,
pubmed-meshheading:15710053-Middle Aged,
pubmed-meshheading:15710053-Positron-Emission Tomography,
pubmed-meshheading:15710053-Pyrimidines,
pubmed-meshheading:15710053-Radioimmunoassay,
pubmed-meshheading:15710053-Receptors, Dopamine D2,
pubmed-meshheading:15710053-Risperidone,
pubmed-meshheading:15710053-Schizophrenia,
pubmed-meshheading:15710053-Scintillation Counting
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia.
|
|
pubmed:affiliation |
Centre for Clinical Research, University of Uppsala, Central Hospital Västerås, Sweden. ola.gefvert@ltvastmanland.se
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
